IMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and Technologies
26 sept. 2023 08h30 HE
|
Imunon, Inc.
Provides a look at the new manufacturing facility in Huntsville, Alabama Introduced as part of IMUNON's newly relaunched website LAWRENCEVILLE, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) --...
IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET
13 sept. 2023 08h30 HE
|
Imunon, Inc.
Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a...
Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer
12 sept. 2023 07h07 HE
|
Panavance Therapeutics Inc.
Results showed antineoplastic activity in pancreatic tumor cell lines Metabolic and transcriptional findings demonstrate a molecular basis to reduce tumor cell proliferation and induce apoptotic cell...
IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET
07 sept. 2023 16h30 HE
|
Imunon, Inc.
Program will feature members of IMUNON executive management along with key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) --...
Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
06 sept. 2023 08h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference
05 sept. 2023 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing novel...
IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus
24 août 2023 16h05 HE
|
Imunon, Inc.
CRADA will evaluate the immunogenicity and efficacy of two DNA-based Lassa virus vaccine candidates in animal models LAWRENCEVILLE, N.J., Aug. 24, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla
14 août 2023 08h30 HE
|
Imunon, Inc.
Renowned scientist will advise on the development of IMUNON’s FixPlas and IndiPlas modalities in immuno-oncology LAWRENCEVILLE, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference
10 août 2023 16h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next...
IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update
10 août 2023 08h00 HE
|
Imunon, Inc.
Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins Today at...